Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 4, 2007 - Issue 4
Submit an article Journal homepage
957
Views
151
CrossRef citations to date
0
Altmetric
Review

Novel approaches to retinal drug delivery

Kumar G Janoria Doctor Fellow and Graduate Research Assistant, University of Missouri-Kansas City, Department of Pharmaceutical Sciences School of Pharmacy, 5005 Rockhill Road, Kansas City MO 64110, USA
, BS,
Sriram Gunda Graduate Research Assistant, University of Missouri-Kansas City, Department of Pharmaceutical Sciences School of Pharmacy, 5005 Rockhill Road, Kansas City MO 64110, USA
, BS,
Sai HS Boddu Graduate Research Assistant, University of Missouri-Kansas City, Department of Pharmaceutical Sciences School of Pharmacy, 5005 Rockhill Road, Kansas City MO 64110, USA
, MS &
Ashim K Mitra Curators' Professor of University of Missouri and Chair University of Missouri-Kansas City, Department of Pharmaceutical Sciences, School of Pharmacy, 5005, Rockhill Road, MO 64110, Kansas City, USA +1 816 235 1615; [email protected]
, PhD
Pages 371-388 | Published online: 07 Aug 2007

Bibliography

  • CUNNINGHAM ET Jr, MARGOLIS TP: Ocular manifestations of HIV infection. N. Engl. J. Med. (1998) 339:236-244.
  • MASUR H, WHITCUP SM, CARTWRIGHT C, POLIS M, NUSSENBLATT R: Advances in the management of AIDS-related cytomegalovirus retinitis. Ann. Intern. Med. (1996) 125:126-136.
  • JONJIC S, MUTTER W, WEILAND F, REDDEHASE MJ, KOSZINOWSKI UH: Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J. Exp. Med. (1989) 169:1199-1212.
  • CROWE SM, CARLIN JB, STEWART KI, LUCAS CR, HOY JF: Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J. Acquir. Immune. Defic. Syndr. (1991) 4:770-776.
  • JACOBSON MA, ZEGANS M, PAVAN PR et al.: Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet (1997) 349:1443-1445.
  • YOUNG RW: Pathophysiology of age-related macular degeneration. Surv. Ophthalmol. (1987) 31:291-306.
  • KLEIN R, KLEIN BE, MOSS SE, DAVIS MD, DEMETS DL: The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology (1984) 91:1464-1474.
  • LOPES DE FARIA JM, JALKH AE, TREMPE CL, MCMEEL JW: Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol. Scand. (1999) 77:170-175.
  • AROCA PR, SALVAT M, FERNANDEZ J, MENDEZ I: Risk factors for diffuse and focal macular edema. J. Diabet. Complications (2004) 18:211-215.
  • PARK CH, JAFFE GJ, FEKRAT S: Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am. J. Ophthalmol. (2003) 136:419-425.
  • CEKIC O, CHANG S, TSENG JJ et al.: Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina (2005) 25:846-850.
  • The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology (1983) 90:121-125.
  • PASTOR JC: Proliferative vitreoretinopathy: an overview. Surv. Ophthalmol. (1998) 43:3-18.
  • KON CH, ASARIA RH, OCCLESTON NL, KHAW PT, AYLWARD GW: Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study. Br. J. Ophthalmol. (2000) 84:506-511.
  • FOSTER RE, MEYERS SM: Recurrent retinal detachment more than 1 year after reattachment. Ophthalmology (2002) 109:1821-1827.
  • ASARIA RH, KON CH, BUNCE C et al.: How to predict proliferative vitreoretinopathy: a prospective study. Ophthalmology (2001) 108:1184-1186.
  • TOGNETTO D, MINUTOLA D, SANGUINETTI G, RAVALICO G: Anatomical and functional outcomes after heavy silicone oil tamponade in vitreoretinal surgery for complicated retinal detachment: a pilot study. Ophthalmology (2005) 112:1574.
  • DUMAS C, ONNET M: Choroidal detachment associated with rhegmatogenous retinal detachment: a risk factor for postoperative PVR? J. Fr. Ophtalmol. (1996) 19:455-463.
  • ASARIA RH, KON CH, BUNCE C, CHARTERIS DG, WONG D, KHAW PT, AYLWARD GW: Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology (2001) 108:1179-1183.
  • CHARTERIS DG, SETHI CS, LEWIS GP, FISHER SK: Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye (2002) 16:369-374.
  • FORRESTER JV: Endogenous posterior uveitis. Br. J. Ophthalmol. (1990) 74:620-623.
  • TOWLER HM, LIGHTMAN S: Sympathetic ophthalmia. Int. Ophthalmol. Clin. (1995) 35:31-42.
  • JABS DA, JOHNS CJ: Ocular involvement in chronic sarcoidosis. Am. J. Ophthalmol. (1986) 102:297-301.
  • RIORDAN-EVA P, LIGHTMAN S: Orbital floor steroid injections in the treatment of uveitis. Eye (1994) 8(Part 1):66-69.
  • LIGHTMAN S: Use of steroids and immunosuppressive drugs in the management of posterior uveitis. Eye (1991) 5(Part 3):294-232.
  • HEMADY R, TAUBER J, FOSTER CS: Immunosuppressive drugs in immune and inflammatory ocular disease. Surv. Ophthalmol. (1991) 35:369-385.
  • SHAH SS, LOWDER CY, SCHMITT MA, WILKE WS, KOSMORSKY GS, MEISLER DM: Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology (1992) 99:1419-1423.
  • KUPPERMANN BD, PETTY JG, RICHMAN DD et al.: Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am. J. Ophthalmol. (1993) 115:575-582.
  • BLOOM JN, PALESTINE AG: The diagnosis of cytomegalovirus retinitis. Ann. Intern. Med. (1988) 109:963-969.
  • PEPOSE JS, HOLLAND GN, NESTOR MS, COCHRAN AJ, FOOS RY: Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease. Ophthalmology (1985) 92:472-484.
  • MUSCH DC, MARTIN DF, GORDON JF, DAVIS MD, KUPPERMANN BD: Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N. Engl. J. Med. (1997) 337:83-90.
  • CUNHA-VAZ J: The blood–ocular barriers. Surv. Ophthalmol. (1979) 23:279-296.
  • CUNHA-VAZ JG: The blood–retinal barriers. Doc. Ophthalmol. (1976) 41:287-327.
  • STEUER H, JAWORSKI A, ELGER B et al.: Functional characterization and comparison of the outer blood–retina barrier and the blood–brain barrier. Invest. Ophthalmol. Vis. Sci. (2005) 46:1047-1053.
  • AUKUNURU JV, SUNKARA G, BANDI N, THORESON WB, KOMPELLA UB: Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor. Pharm. Res. (2001) 18:565-572.
  • KENNEDY BG, MANGINI NJ: P-glycoprotein expression in human retinal pigment epithelium. Mol. Vis. (2002) 8:422-430.
  • GREENWOOD J: Characterization of a rat retinal endothelial cell culture and the expression of P-glycoprotein in brain and retinal endothelium in vitro. J. Neuroimmunol. (1992) 39:123-132.
  • GEROSKI DH, EDELHAUSER HF: Drug delivery for posterior segment eye disease. Invest. Ophthalmol. Vis. Sci. (2000) 41:961-964.
  • HUGHES PM, OLEJNIK O, CHANG-LIN JE, WILSON CG: Topical and systemic drug delivery to the posterior segments. Adv. Drug Deliv. Rev. (2005) 57:2010-2032.
  • BOURLAIS CL, ACAR L, ZIA H, SADO PA, NEEDHAM T, LEVERGE R: Ophthalmic drug delivery systems – recent advances. Prog. Retin Eye Res. (1998) 17:33-58.
  • AHMED I, PATTON TF: Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci. (1985) 26:584-587.
  • BILL A: The drainage of albumin from the uvea. Exp. Eye Res. (1964) 75:179-187.
  • CHAPMAN JM, CHEEKS L, GREEN K: Interactions of benzalkonium chloride with soft and hard contact lenses. Arch. Ophthalmol. (1990) 108:244-246.
  • KAUR IP, KANWAR M: Ocular preparations: the formulation approach. Drug Dev. Ind. Pharm. (2002) 28:473-493.
  • LALEZARI JP, STAGG RJ, KUPPERMANN BD et al.: Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann. Intern. Med. (1997) 126:257-263.
  • MOCHIZUKI M, IKEDA E, YOSHIMURA K et al.: Treatment of cytomegalovirus retinitis in AIDS with an intraocular sustained-release ganciclovir implant. Nippon Ganka Gakkai Zasshi (1998) 102:515-521.
  • BARZA M: Factors affecting the intraocular penetration of antibiotics. The influence of route, inflammation, animal species and tissue pigmentation. Scand. J. Infect. Dis. Suppl. (1978):151-159.
  • TAYANITHI P: Treatment of cytomegalovirus retinitis in acquired immunodeficiency syndrome with intravitreal ganciclovir implant. J. Med. Assoc. Thai. (2001) 84 (Suppl. 1):S142-S147.
  • MONTERO MC, PASTOR M, BUENESTADO C, LLUCH A, ATIENZA M: Intravitreal ganciclovir for cytomegalovirus retinitis in patients with AIDS. Ann. Pharmacother. (1996) 30:717-723.
  • LOPEZ-CORTES LF, PASTOR-RAMOS MT, RUIZ-VALDERAS R et al.: Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci. (2001) 42:1024-1028.
  • CHENG L, HOSTETLER KY, LEE J et al.: Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. Invest. Ophthalmol. Vis. Sci. (2004) 45:4138-4144.
  • FISHER JP, CIVILETTO SE, FORSTER RK: Toxicity, efficacy, and clearance of intravitreally injected of cefazolin. Arch. Ophthalmol. (1982) 100:650-652.
  • IYER MN, HE F, WENSEL TG, MIELER WF, BENZ MS, HOLZ ER: Intravitreal clearance of moxifloxacin. Trans. Am. Ophthalmol. Soc. (2005) 103:76-81; discussion 81-73.
  • BARZA M, LYNCH E, BAUM JL: Pharmacokinetics of newer cephalosporins after subconjunctival and intravitreal injection in rabbits. Arch. Ophthalmol. (1993) 111:121-125.
  • KISHORE K, CONWAY MD, PEYMAN GA: Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis. Ophthalmic Surg. Lasers (2001) 32:183-192.
  • EL-MASSRY A, MEREDITH TA, AGUILAR HE et al.: Aminoglycoside levels in the rabbit vitreous cavity after intravenous administration. Am. J. Ophthalmol. (1996) 122:684-689.
  • KIM H, CSAKY KG, GRAVLIN L et al.: Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina (2006) 26:523-530.
  • KIM H, CSAKY KG, CHAN CC et al.: The pharmacokinetics of rituximab following an intravitreal injection. Exp. Eye Res. (2006) 82:760-766.
  • HUGHES MS, SANG DN: Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg. Lasers Imaging (2006) 37:446-454.
  • MARMOR MF, NEGI A, MAURICE DM: Kinetics of macromolecules injected into the subretinal space. Exp. Eye Res. (1985) 40:687-696.
  • GHATE D, EDELHAUSER HF: Ocular drug delivery. Expert Opin. Drug Deliv. (2006) 3:275-287.
  • MAURICE D: Review: practical issues in intravitreal drug delivery. J. Ocul. Pharmacol. Ther. (2001) 17:393-401.
  • BAUM J, PEYMAN GA, BARZA M: Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis. III. Consensus. Surv. Ophthalmol. (1982) 26:204-206.
  • CAMPOCHIARO PA, CONWAY BP: Aminoglycoside toxicity – a survey of retinal specialists. Implications for ocular use. Arch. Ophthalmol. (1991) 109:946-950.
  • MARTIN DF, SIERRA-MADERO J, WALMSLEY S et al.: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N. Engl. J. Med. (2002) 346:1119-1126.
  • VELEZ G, WHITCUP SM: New developments in sustained release drug delivery for the treatment of intraocular disease. Br. J. Ophthalmol. (1999) 83:1225-1229.
  • AUSAYAKHUN S, YUVAVES P, NGAMTIPHAKOM S, PRASITSILP J: Treatment of cytomegalovirus retinitis in AIDS patients with intravitreal ganciclovir. J. Med. Assoc. Thai. (2005) 88 (Suppl. 9):S15-S20.
  • BAUDOUIN C, CHASSAIN C, CAUJOLLE C, GASTAUD P: Treatment of cytomegalovirus retinitis in AIDS patients using intravitreal injections of highly concentrated ganciclovir. Ophthalmologica (1996) 210:329-335.
  • FUJINO Y, NAGATA Y, MIYOSHI M et al.: Intravitreal injection of ganciclovir in AIDS patients with cytomegalovirus retinitis. Nippon Ganka Gakkai Zasshi (1996) 100:634-640.
  • YOUNG S, MCCLUSKEY P, MINASSIAN DC et al.: Retinal detachment in cytomegalovirus retinitis: intravenous versus intravitreal therapy. Clin. Exp. Ophthalmol. (2003) 31:96-102.
  • HYNDIUK RA, REAGAN MG: Radioactive depot-corticosteroid penetration into monkey ocular tissue. I. Retrobulbar and systemic administration. Arch. Ophthalmol. (1968) 80:499-503.
  • TRIVEDI H, TODKAR H, ARBHAVE V, BHATIA P: Ocular anaesthesia for cataract surgery. Lancet (2003) 3:1312-1313, 1319.
  • EBNER R, DEVOTO MH, WEIL D et al.: Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br. J. Ophthalmol. (2004) 88:1380-1386.
  • VAN den Berg AA: An audit of peribulbar blockade using 15 mm, 25 mm and 37.5 mm needles, and sub-Tenon's injection. Anaesthesia (2004) 59:775-780.
  • RIPART J, LEFRANT JY, DE LA COUSSAYE JE, PRAT-PRADAL D, VIVIEN B, ELEDJAM JJ: Peribulbar versus retrobulbar anesthesia for ophthalmic surgery: an anatomical comparison of extraconal and intraconal injections. Anesthesiology (2001) 94:56-62.
  • WATKINS R, BEIGI B, YATES M, CHANG B, LINARDOS E: Intraocular pressure and pulsatile ocular blood flow after retrobulbar and peribulbar anaesthesia. Br. J. Ophthalmol. (2001) 85:796-798.
  • DAVIS DB II, MANDEL MR: Efficacy and complication rate of 16,224 consecutive peribulbar blocks. A prospective multicenter study. J. Cataract Refract Surg. (1994) 20:327-337.
  • KLEIN ML, JAMPOL LM, CONDON PI, RICE TA, SERJEANT GR: Central retinal artery occlusion without retrobulbar hemorrhage after retrobulbar anesthesia. Am. J. Ophthalmol. (1982) 93:573-577.
  • MORGAN JP, CLEARKIN LG: Rapid onset of ptosis indicates accurate intraconal placement during retrobulbar anaesthetic injection. Br. J. Ophthalmol. (2001) 85:363-365.
  • ROMAN SJ, CHONG SIT, DA, BOUREAU CM, AUCLIN FX, ULLERN MM: Sub-Tenon's anaesthesia: an efficient and safe technique. Br. J. Ophthalmol. (1997) 81:673-676.
  • WYLIE J, HENDERSON M, DOYLE M, HICKEY-DWYER M: Persistent binocular diplopia following cataract surgery: aetiology and management. Eye (1994) 8(Part 5):543-532.
  • CANAVAN KS, DARK A, GARRIOCH MA: Sub-Tenon's administration of local anaesthetic: a review of the technique. Br. J. Anaesth. (2003) 90:787-793.
  • KIM TW, LINDSEY JD, AIHARA M, ANTHONY TL, WEINREB RN: Intraocular distribution of 70-kDa dextran after subconjunctival injection in mice. Invest. Ophthalmol. Vis. Sci. (2002) 43:1809-1816.
  • AMBATI J, GRAGOUDAS ES, MILLER JW et al.: Transscleral delivery of bioactive protein to the choroid and retina. Invest. Ophthalmol. Vis. Sci. (2000) 41:1186-1191.
  • BITO LZ, BAROODY RA: The penetration of exogenous prostaglandin and arachidonic acid into, and their distribution within, the mammalian eye. Curr. Eye Res. (1981) 1:659-669.
  • WEIJTENS O, SCHOEMAKER RC, LENTJES EG, ROMIJN FP, COHEN AF, VAN MEURS JC: Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. Ophthalmology (2000) 107:1932-1938.
  • ZIGNANI M, EINMAHL S, BAEYENS V et al.: A poly(ortho ester) designed for combined ocular delivery of dexamethasone sodium phosphate and 5-fluorouracil: subconjunctival tolerance and in vitro release. Eur. J. Pharm. Biopharm. (2000) 50:251-255.
  • GEROSKI DH, EDELHAUSER HF: Transscleral drug delivery for posterior segment disease. Adv. Drug Deliv. Rev. (2001) 52:37-48.
  • MAINARDES RM, SILVA LP: Drug delivery systems: past, present, and future. Curr. Drug Targets (2004) 5:449-455.
  • FISHMAN PH, PEYMAN GA, LESAR T: Intravitreal liposome-encapsulated gentamicin in a rabbit model. Prolonged therapeutic levels. Invest. Ophthalmol. Vis. Sci. (1986) 27:1103-1106.
  • ZENG S, HU C, WEI H et al.: Intravitreal pharmacokinetics of liposome-encapsulated amikacin in a rabbit model. Ophthalmology (1993) 100:1640-1644.
  • LIU KR, PEYMAN GA, KHOOBEHI B, ALKAN H, FISCELLA R: Intravitreal liposome-encapsulated trifluorothymidine in a rabbit model. Ophthalmology (1987) 94:1155-1159.
  • PEYMAN GA, KHOOBEHI B, TAWAKOL M et al.: Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model. Retina (1987) 7:227-229.
  • ALGHADYAN AA, PEYMAN GA, KHOOBEHI B, LIU KR: Liposome-bound cyclosporine: retinal toxicity after intravitreal injection. Int. Ophthalmol. (1988) 12:105-107.
  • ALGHADYAN AA, PEYMAN GA, KHOOBEHI B, MILNER S, LIU KR: Liposome-bound cyclosporine: clearance after intravitreal injection. Int. Ophthalmol. (1988) 12:109-112.
  • PEYMAN GA, GANIBAN GJ: Delivery systems for intraocular routes. Adv. Drug Deliv. Rev. (1995) 16:107-112.
  • AKULA SK, MA PE, PEYMAN GA et al.: Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. Br. J. Ophthalmol. (1994) 78:677-680.
  • DIAZ-Llopis M, Martos MJ, Espana E et al.: Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Eperimental toxicity and pharmacokinetics, and clinical trial. Doc. Ophthalmol. (1992) 82:297-305.
  • PEYMAN GA, SCHULMAN JA, KHOOBEHI B, ALKAN HM, TAWAKOL ME, MANI H: Toxicity and clearance of a combination of liposome-encapsulated ganciclovir and trifluridine. Retina (1989) 9:232-236.
  • COLTHURST MJ, WILLIAMS RL, HISCOTT PS, GRIERSON I: Biomaterials used in the posterior segment of the eye. Biomaterials (2000) 21:649-665.
  • LE Bourlais C, CHEVANNE F, ROPERT P et al.: Release kinetics of liposome-encapsulated ganciclovir after intravitreal injection in rabbits. J. Microencapsul. (1996) 13:473-480.
  • OGURA’ Y: Drug delivery to the posterior segments of the eye. Adv. Drug Deliv. Rev. (2001) 52:1-3.
  • CHENG L, HOSTETLER KY, CHAIDHAWANGUL S et al.: Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. Invest. Ophthalmol. Vis. Sci. (2000) 41:1523-1532.
  • BOCHOT A, COUVREUR P, FATTAL E: Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog. Retin Eye Res. (2000) 19:131-147.
  • OGURA Y, GURAN T, SHAHIDI M, MORI MT, ZEIMER RC: Feasibility of targeted drug delivery to selective areas of the retina. Invest. Ophthalmol. Vis. Sci. (1991) 32:2351-2356.
  • ZEIMER RC, KHOOBEHI B, NIESMAN MR, MAGIN RL: A potential method for local drug and dye delivery in the ocular vasculature. Invest. Ophthalmol. Vis. Sci. (1988) 29:1179-1183.
  • DESHPANDE AA, HELLER J, GURNY R: Bioerodible polymers for ocular drug delivery. Crit. Rev. Ther. Drug Carrier Syst. (1998) 15:381-420.
  • HELLER J: Ocular delivery using poly(ortho esters). Adv. Drug Deliv. Rev. (2005) 57:2053-2062.
  • KIMURA H, OGURA Y: Biodegradable polymers for ocular drug delivery. Ophthalmologica (2001) 215:143-155.
  • GIORDANO GG, CHEVEZ-BARRIOS P, REFOJO MF, GARCIA CA: Biodegradation and tissue reaction to intravitreous biodegradable poly(D,L-lactic-co-glycolic)acid microspheres. Curr. Eye Res. (1995) 14:761-768.
  • KHOOBEHI B, STRADTMANN MO, PEYMAN GA, ALY OM: Clearance of sodium fluorescein incorporated into microspheres from the vitreous after intravitreal injection. Ophthalmic Surg. (1991) 22:175-180.
  • MORITERA T, OGURA Y, YOSHIMURA N, HONDA Y, WADA R, HYON SH, IKADA Y: Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. (1992) 33:3125-3130.
  • GIORDANO GG, REFOJO MF, ARROYO MH: Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR. Invest. Ophthalmol. Vis. Sci. (1993) 34:2743-2751.
  • MORITERA T, OGURA Y, HONDA Y, WADA R, HYON SH, IKADA Y: Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest. Ophthalmol. Vis. Sci. (1991) 32:1785-1790.
  • PEYMAN GA, CONWAY M, KHOOBEHI B, SOIKE K: Clearance of microsphere-entrapped 5-fluorouracil and cytosine arabinoside from the vitreous of primates. Int. Ophthalmol. (1992) 16:109-113.
  • VELOSO AA Jr, ZHU Q, HERRERO-VANRELL R, REFOJO MF: Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus. Invest. Ophthalmol. Vis. Sci. (1997) 38:665-675.
  • HE Y, WANG JC, LIU YL, MA ZZ, ZHU XA, ZHANG Q: Therapeutic and toxicological evaluations of cyclosporine a microspheres as a treatment vehicle for uveitis in rabbits. J. Ocul. Pharmacol. Ther. (2006) 22:121-131.
  • DUVVURI S, JANORIA KG, MITRA AK: Development of a novel formulation containing poly (D,L-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir. J. Control. Release (2005) 108:282-293.
  • DUVVURI S, JANORIA KG, PAL D, MITRA AK: Controlled delivery of ganciclovir to the retina with drug loaded PLGA microspheres dispersed in PLGA-PEG-PLGA gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis. J. Ocul. Pharmacol. Ther. (2007) 23(3):264-274.
  • MERODIO M, IRACHE JM, VALAMANESH F, MIRSHAHI M: Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials (2002) 23:1587-1594.
  • DE Kozak Y, Andrieux K, Villarroya H et al.: Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur. J. Immunol. (2004) 34:3702-3712.
  • BOURGES JL, GAUTIER SE, DELIE F et al.: Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Ophthalmol. Vis. Sci. (2003) 44:3562-3569.
  • SAKURAI E, OZEKI H, KUNOU N, OGURA Y: Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res. (2001) 33:31-36.
  • SANBORN GE, ANAND R, TORTI RE et al.: Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch. Ophthalmol. (1992) 110:188-195.
  • HASHIZOE M, OGURA Y, TAKANASHI T, KUNOU N, HONDA Y, IKADA Y: Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits. Curr. Eye Res. (1997) 16:633-639.
  • KIMURA H, OGURA Y, HASHIZOE M, NISHIWAKI H, HONDA Y, IKADA Y: A new vitreal drug delivery system using an implantable biodegradable polymeric device. Invest. Ophthalmol. Vis. Sci. (1994) 35:2815-2819.
  • LIM JI, WOLITZ RA, DOWLING AH, BLOOM HR, IRVINE AR, SCHWARTZ DM: Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am. J. Ophthalmol. (1999) 127:288-293.
  • JAFFE GJ, BEN-NUN J, GUO H, DUNN JP, ASHTON P: Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology (2000) 107:2024-2033.
  • JAFFE GJ, PEARSON PA, ASHTON P: Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina (2000) 20:402-403.
  • JAFFE GJ, YANG CS, WANG XC, COUSINS SW, GALLEMORE RP, ASHTON P: Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology (1998) 105:46-56.
  • JAFFE GJ, MCCALLUM RM, BRANCHAUD B, SKALAK C, BUTUNER Z, ASHTON P: Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology (2005) 112:1192-1198.
  • YANG CS, KHAWLY JA, HAINSWORTH DP et al.: An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch. Ophthalmol. (1998) 116:69-77.
  • OKABE K, KIMURA H, OKABE J, KATO A, KUNOU N, OGURA Y: Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest. Ophthalmol. Vis. Sci. (2003) 44:2702-2707.
  • KUNOU N, OGURA Y, HASHIZOE M, HONDA Y, HYON S, IKADA Y: Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. J. Control. Release (1995) 37:143-215.
  • KUNOU N, OGURA Y, YASUKAWA T et al.: Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J. Control. Release (2000) 68:263-271.
  • SAKURAI E, MATSUDA Y, OZEKI H, KUNOU N, NAKAJIMA K, OGURA Y: Scleral plug of biodegradable polymers containing ganciclovir for experimental cytomegalovirus retinitis. Invest. Ophthalmol. Vis. Sci. (2001) 42:2043-2048.
  • YASUKAWA T, KIMURA H, KUNOU N et al.: Biodegradable scleral implant for intravitreal controlled release of ganciclovir. Graefes Arch. Clin. Exp. Ophthalmol. (2000) 238:186-190.
  • MIYAMOTO H, OGURA Y, HASHIZOE M, KUNOU N, HONDA Y, IKADA Y: Biodegradable scleral implant for intravitreal controlled release of fluconazole. Curr. Eye Res. (1997) 16:930-935.
  • HASHIZOE M, OGURA Y, KIMURA H et al.: Scleral plug of biodegradable polymers for controlled drug release in the vitreous. Arch. Ophthalmol. (1994) 112:1380-1384.
  • HASHIZOE M, OGURA Y, TAKANASHI T, KUNOU N, HONDA Y, IKADA Y: Implantable biodegradable polymeric device in the treatment of experimental proliferative vitreoretinopathy. Curr. Eye Res. (1995) 14:473-477.
  • RUBSAMEN PE, DAVIS PA, HERNANDEZ E, O'GRADY GE, COUSINS SW: Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch. Ophthalmol. (1994) 112:407-413.
  • ZHOU T, LEWIS H, FOSTER RE, SCHWENDEMAN SP: Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J. Control. Release (1998) 55:281-295.
  • SAKURAI E, NOZAKI M, OKABE K, KUNOU N, KIMURA H, OGURA Y: Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest. Ophthalmol. Vis. Sci. (2003) 44:4845-4852.
  • MORITA Y, OHTORI A, KIMURA M AND TOJO K: Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid) implants. Biol. Pharm. Bull. (1998) 21:188-190.
  • OKABE J, KIMURA H, KUNOU N, OKABE K, KATO A, OGURA Y: Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest. Ophthalmol. Vis. Sci. (2003) 44:740-744.
  • DIAS CS, ANAND BS, MITRA AK: Effect of mono- and di-acylation on the ocular disposition of ganciclovir: physicochemical properties, ocular bioreversion, and antiviral activity of short chain ester prodrugs. J. Pharm. Sci. (2002) 91:660-668.
  • DUN Y, MYSONA B, ITAGAKI S, MARTIN-STUDDARD A, GANAPATHY V, SMITH SB: Functional and molecular analysis of D-serine transport in retinal Muller cells. Exp. Eye Res. (2007) 84:191-199.
  • GERHART DZ, LEINO RL, DREWES LR: Distribution of monocarboxylate transporters MCT1 and MCT2 in rat retina. Neuroscience (1999) 92:367-375.
  • KANSARA V, LUO S, BALASUBRAHMANYAM B, PAL D, MITRA AK: Biotin uptake and cellular translocation in human derived retinoblastoma cell line (Y-79): a role of hSMVT system. Int. J. Pharm. (2006) 312:43-52.
  • KANSARA V, PAL D, JAIN R, MITRA AK: Identification and functional characterization of riboflavin transporter in human-derived retinoblastoma cell line (Y-79): mechanisms of cellular uptake and translocation. J. Ocul. Pharmacol. Ther. (2005) 21:275-287.
  • WIESSNER M, FLETCHER EL, FISCHER F, RAUEN T: Localization and possible function of the glutamate transporter, EAAC1, in the rat retina. Cell Tissue Res. (2002) 310:31-40.
  • LEE VH: Membrane transporters. Eur. J. Pharm. Sci. (2000) 11 (Suppl. 2):S41-S50.
  • ADIBI SA: Renal assimilation of oligopeptides: physiological mechanisms and metabolic importance. Am. J. Physiol. (1997) 272:E723-E736.
  • SALA-RABANAL M, Loo DD, Hirayama BA, Turk E, Wright EM: Molecular interactions between dipeptides, drugs and the human intestinal H+-oligopeptide cotransporter hPEPT1. J. Physiol. (2006) 574:149-166.
  • NOVOTNY A, XIANG J, STUMMER W, TEUSCHER NS, SMITH DE, KEEP RF: Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus. J. Neurochem. (2000) 75:321-328.
  • ANAND BS, PATEL J, MITRA AK: Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive inhibition of glycylsarcosine transport in human intestinal cell line-Caco-2. J. Pharmacol. Exp. Ther. (2003) 304:781-791.
  • MAJUMDAR S, NASHED YE, PATEL K et al.: Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. J. Ocul. Pharmacol. Ther. (2005) 21:463-474.
  • ANAND BS, MITRA AK: Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea. Pharm. Res. (2002) 19:1194-1202.
  • ATLURI H, ANAND BS, PATEL J, MITRA AK: Mechanism of a model dipeptide transport across blood–ocular barriers following systemic administration. Exp. Eye Res. (2004) 78:815-822.
  • MAJUMDAR S, KANSARA V, MITRA AK: Vitreal pharmacokinetics of dipeptide monoester prodrugs of ganciclovir. J. Ocul. Pharmacol. Ther. (2006) 22:231-241.
  • ANAND BS, KATRAGADDA S, NASHED YE, MITRA AK: Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium. Curr. Eye Res. (2004) 29:153-166.
  • JAIN-Vakkalagadda B, Pal D, Gunda S, Nashed Y, Ganapathy V, Mitra AK: Identification of a Na+-dependent cationic and neutral amino acid transporter, B(0,+), in human and rabbit cornea. Mol. Pharm. (2004) 1:338-346.
  • BONEN A: The expression of lactate transporters (MCT1 and MCT4) in heart and muscle. Eur. J. Appl. Physiol. (2001) 86:6-11.
  • HALESTRAP AP, PRICE NT: The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem. J. (1999) 343 (Part 2):281-299.
  • LIN RY, VERA JC, CHAGANTI RS, GOLDE DW: Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter. J. Biol. Chem. (1998) 273:28959-28965.
  • PHILP NJ, YOON H, GROLLMAN EF: Monocarboxylate transporter MCT1 is located in the apical membrane and MCT3 in the basal membrane of rat RPE. Am. J. Physiol. (1998) 274:R1824-R1828.
  • HOSOYA K, KONDO T, TOMI M, TAKANAGA H, OHTSUKI S, TERASAKI T: MCT1-mediated transport of L-lactic acid at the inner blood–retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina. Pharm. Res. (2001) 18:1669-1676.
  • TSUJI A, TAMAI I, NAKANISHI M, TERASAKI T, HAMANO S: Intestinal brush–border transport of the oral cephalosporin antibiotic, cefdinir, mediated by dipeptide and monocarboxylic acid transport systems in rabbits. J. Pharm. Pharmacol. (1993) 45:996-998.
  • LI YH, ITO K, TSUDA Y, KOHDA R, YAMADA H, ITOH T: Mechanism of intestinal absorption of an orally active beta-lactam prodrug: uptake and transport of carindacillin in Caco-2 cells. J. Pharmacol. Exp. Ther. (1999) 290:958-964.
  • CHANCY CD, KEKUDA R, HUANG W et al.: Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epithelium. J. Biol. Chem. (2000) 275:20676-20684.
  • KANSARA V, MITRA AK: Evaluation of an ex vivo model implication for carrier-mediated retinal drug delivery. Curr. Eye Res. (2006) 31:415-426.
  • DUVVURI S, GANDHI MD, MITRA AK: Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. Curr. Eye Res. (2003) 27:345-353.
  • KANIKKANNAN N: Iontophoresis-based transdermal delivery systems. Bio. Drugs (2002) 16:339-347.
  • SIMS SM, HIGUCHI WI, SRINIVASAN V: Skin alteration and convective solvent flow effects during iontophoresis. II. Monovalent anion and cation transport across human skin. Pharm. Res. (1992) 9:1402-1409.
  • SINGH J, MAIBACH HI: Topical iontophoretic drug delivery in vivo: historical development, devices and future perspectives. Dermatology (1993) 187:235-238.
  • PHIPPS JB, PADMANABHAN RV, LATTIN GA: Iontophoretic delivery of model inorganic and drug ions. J. Pharm. Sci. (1989) 78:365-369.
  • KARI B: Control of blood glucose levels in alloxan-diabetic rabbits by iontophoresis of insulin. Diabetes (1986) 35:217-221.
  • D'Emanuele A, STANIFORTH JN: An electrically modulated drug delivery device. III. Factors affecting drug stability during electrophoresis. Pharm. Res. (1992) 9:312-315.
  • ZHU H, LI SK, PECK KD, MILLER DJ, HIGUCHI WI: Improvement on conventional constant current DC iontophoresis: a study using constant conductance AC iontophoresis. J. Control. Release (2002) 82:249-261.
  • KALIA YN, NAIK A, GARRISON J, GUY RH: Iontophoretic drug delivery. Adv. Drug Deliv. Rev. (2004) 56:619-658.
  • WELSH RG, FOWLER JE, SHAPLAND JE: Iontophoretic drug delivery system. Semin. Interv. Cardiol. (1996) 1:40-42.
  • BURNETTE RR, ONGPIPATTANAKUL B: Characterization of the pore transport properties and tissue alteration of excised human skin during iontophoresis. J. Pharm. Sci. (1988) 77:132-137.
  • FISCHER GA, PARKINSON TM, SZLEK MA: OcuPhor – the future of ocular drug delivery. Drug Deliv. Technol. (2002) 2:50-52.
  • ELJARRAT-Binstock E, RAISKUP F, STEPENSKY D, DOMB AJ, FRUCHT-PERY J: Delivery of gentamicin to the rabbit eye by drug-loaded hydrogel iontophoresis. Invest. Ophthalmol. Vis. Sci. (2004) 45:2543-2548.
  • VOLLMER DL, SZLEK MA, KOLB K, LLOYD LB, PARKINSON TM: In vivo transscleral iontophoresis of amikacin to rabbit eyes. J. Ocul. Pharmacol. Ther. (2002) 18:549-558.
  • HOBDEN JA, ROOTMAN DS, O'CALLAGHAN RJ, HILL JM: Iontophoretic application of tobramycin to uninfected and Pseudomonas aeruginosa-infected rabbit corneas. Antimicrob. Agents Chemother. (1988) 32:978-981.
  • BARZA M, PECKMAN C, BAUM J: Transscleral iontophoresis of cefazolin, ticarcillin, and gentamicin in the rabbit. Ophthalmology (1986) 93:133-139.
  • BATHEJA P, THAKUR R, MICHNIAK B: Transdermal iontophoresis. Expert Opin. Drug Deliv. (2006) 3:127-138.
  • MYLES ME, NEUMANN DM, HILL JM: Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv. Drug Deliv. Rev. (2005) 57:2063-2079.
  • GRIFFIN JE, TOUCHSTONE JC: Ultrasonic movement of cortisol into pig tissues. I. Movement into skeletal muscle. Am. J. Phys. Med. (1963) 42:77-85.
  • ZDERIC V, VAEZY S, MARTIN RW AND CLARK JI: Ocular drug delivery using 20-kHz ultrasound. Ultrasound Med. Biol. (2002) 28:823-829.
  • ZDERIC V, CLARK JI, MARTIN RW AND VAEZY S: Ultrasound-enhanced transcorneal drug delivery. Cornea (2004) 23:804-811.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.